Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.

摘要: BACKGROUND: Several studies have demonstrated the efficacy of systemic oxaliplatin (Oxa) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for treatment colorectal liver metastases (CRLM). However, nothing is presently known about pharmacokinetics Oxa administered via hepatic artery only very little feasibility toxicity used infusion (HAI). PATIENTS AND METHODS: We designed a phase II trial using 5-FU/FA mitomycin C (MMC) HAI patients isolated non-resectable CRLM. (130 mg/m2) was delivered on day (d) 1 as 120-min followed by FA (140 10 min 5-FU (480 120 from d1 to d5 MMC (7 30 every 35 days. For pharmacokinetics, peripheral venous blood collected before, during after arterial infusion. Oxaliplatin determined liquid chromatography post-column derivatization ultra filtrate. RESULTS: A total 33 cycles were 5 tolerable toxicity, which mainly consisted grade I nausea, vomiting, leucopenia, thrombopenia abdominal pain. During 4 nausea/vomiting III degree occurred, 3 diarrhoea pain degree. No neurotoxicity > or = no catheter occlusion observed. Staging showed PR PD. Pharmacokinetic analysis revealed an AUC value 85.3 micrograms x min/ml HAI. Recalculating these values previously reported administration (161 min/ml) extraction ratio 0.47 Oxa. CONCLUSION: conclude our results that may be feasible protocol without major especially avoiding higher neurotoxicity. This probably attributable low bioavailability